AR061947A1 - Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina - Google Patents

Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina

Info

Publication number
AR061947A1
AR061947A1 ARP080100070A ARP080100070A AR061947A1 AR 061947 A1 AR061947 A1 AR 061947A1 AR P080100070 A ARP080100070 A AR P080100070A AR P080100070 A ARP080100070 A AR P080100070A AR 061947 A1 AR061947 A1 AR 061947A1
Authority
AR
Argentina
Prior art keywords
complex
gch
clinical
human
corionic
Prior art date
Application number
ARP080100070A
Other languages
English (en)
Inventor
Oscar Belluscio Daniel
Ariel Vaney Sergio
Original Assignee
Oscar Belluscio Daniel
Ariel Vaney Sergio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oscar Belluscio Daniel, Ariel Vaney Sergio filed Critical Oscar Belluscio Daniel
Priority to ARP080100070A priority Critical patent/AR061947A1/es
Publication of AR061947A1 publication Critical patent/AR061947A1/es
Priority to US12/318,073 priority patent/US20090176697A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se da a conocer la utilidad clínica de la Gonadotrofina Coriónica Humana (GCH) complejada a Ciclodextrinas administrable por vía oral, para su aplicación en diferentes patologías y el método para su obtención. La presente contempla el uso de las ciclodextrinas como carriers (transportadores) y su capacidad para la formación de complejos de inclusión con moléculas bioactivas (tales como la GCH), permitiendo la actividad clínica de la GCH por vía oral, facilitando la administración de una medicación que originalmente se prescribe en forma inyectable. Específicamente el objetivo de la misma es la creación de complejos GCH (Gonadotrofina Coriónica Humana) con ciclodextrinas y su utilización clínica en los desórdenes de diferentes patologías, por medio de formulaciones farmacéuticas de uso oral.
ARP080100070A 2008-01-08 2008-01-08 Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina AR061947A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP080100070A AR061947A1 (es) 2008-01-08 2008-01-08 Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina
US12/318,073 US20090176697A1 (en) 2008-01-08 2008-12-22 Method to obtain the human Chorionic Gonadotropin (hCG)/cyclodextrin complex for oral administration, product obtained by this method and clinical and therapeutic use of the complex human Chorionic Gonadotropin (hCG)/cyclodextrin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP080100070A AR061947A1 (es) 2008-01-08 2008-01-08 Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina

Publications (1)

Publication Number Publication Date
AR061947A1 true AR061947A1 (es) 2008-08-10

Family

ID=40845060

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100070A AR061947A1 (es) 2008-01-08 2008-01-08 Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina

Country Status (2)

Country Link
US (1) US20090176697A1 (es)
AR (1) AR061947A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole

Also Published As

Publication number Publication date
US20090176697A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
ES2527200T3 (es) Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana
EP3248609A3 (en) N-acyldipeptide derivatives and their uses
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
JP2012092110A5 (es)
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
AR069211A1 (es) Derivados de acidos de 1,2,4-oxadiazol ciclobutanoamino carboxilicos, una composicion farmaceutica, proceso de preparacion del compuesto y su uso para preparar medicamentos
WO2008146016A3 (en) Cyclodextrins for administering fatty acids in tablets
BR112015010980A8 (pt) composição de veículos e formas farmacêuticas de liberação prolongada e aumento de biodisponibilidade de antibacterianos, anticoccidianos e outros fármacos em aves comerciais e porcos
ZA201006639B (en) Nanoparticle carriers for drug administration and process for producing the same
BR112013028820A2 (pt) alimento medicinal para declínio cognitivo
ECSP12012274A (es) Composición farmacèutica de ibuprofeno para inyecciòn
CO6620016A2 (es) Métodos de tratamiento de transtorno ópticos
AR061947A1 (es) Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina
Kang et al. A prospective trial comparing 4 L-polyethylene glycol with 2 L-polyethylene glycol plus bisacodyl tablets for colon preparation
BR112014013723A8 (pt) formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico
Bhatia et al. Pattern of Psychosexual Disorders among males attending Psychiatry OPD of a Tertiary Care Hospital.
CY1117873T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ (1r,4r)-6’-ΦΘΟΡΟ-(Ν,Ν-ΔΙΜΕΘΥΛΟ)-4-ΦΑΙΝΥΛΟ-4΄, 9΄-ΔΙΥΔΡΟ-3’Η-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1 '-ΠΥΡΑΝΟ-[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ ΚΑΙ ΘΕΙΙΚΟΥ ΟΞΕΟΣ
EP2343089A4 (en) USE OF XYLITOL OR DERIVATIVES THEREOF FOR MASKING THE TASTE OF CHEMOTHERAPEUTIC MEDICAMENTS OF THE CHINOLO-N-NAPHTHYRIDONE-CARBOXYLIC ACID GROUP FOR PIG DICULTINATION
Gu et al. Influence of simvastatin on pharmacokinetics/pharmacodynamics of aspirin after oral co-administration in healthy volunteers
YANG Research progress of nanoemulsions' applications in improving the bioavailability of poor water-soluble drugs
Prokai-Tatrai Neuroprotective Strategies 2013
Lee et al. Continuous hydrocortisone infusion in severe pediatric community-acquired pneumonia (CAP).

Legal Events

Date Code Title Description
FB Suspension of granting procedure